Mirae Asset Global ETFs Holdings
ELVN icon

Mirae Asset Global ETFs Holdings’s Enliven Therapeutics ELVN Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Buy
19,729
+1,280
+7% +$54.3K ﹤0.01% 1629
2026
Q1 		$723K Buy
18,449
+162
+0.9% +$4.49K ﹤0.01% 1683
2025
Q4 		$282K Sell
18,287
-1,242
-6% -$24.7K ﹤0.01% 2180
2025
Q3 		$400K Buy
19,529
+1,873
+11% +$37.8K ﹤0.01% 1974
2025
Q2 		$354K Sell
17,656
-4,073
-19% -$77.1K ﹤0.01% 1989
2025
Q1 		$428K Buy
21,729
+1,693
+8% +$36.4K ﹤0.01% 1954
2024
Q4 		$451K Buy
20,036
+718
+4% +$18.6K ﹤0.01% 1975
2024
Q3 		$493K Buy
19,318
+7,929
+70% +$184K ﹤0.01% 1919
2024
Q2 		$266K Buy
+11,389
New +$240K ﹤0.01% 2121

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's ELVN Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Enliven Therapeutics (ELVN) stake by 6.9% in Q2 2026, buying an estimated $54.3K and bringing the position to 19,729 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #1629.

Mirae Asset Global ETFs Holdings first reported a position in ELVN in Q2 2024 and has held it in 9 quarters since. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 19,729 shares of Enliven Therapeutics worth $1M as of Q2 2026.
  • Mirae Asset Global ETFs Holdings bought 1,280 Enliven Therapeutics shares in Q2 2026, an estimated $54.3K.
  • Enliven Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1629 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.